Swedish Orphan Biovitrum Articles
SOBI to distribute Exelixis' cancer drug Cometriq in EU
22 February 2013
SOBI links with Savient for co-promotion of Kineret in USA
19 February 2013
SOBI gains distribution rights for Megace, Monopril, Cefzil and Duricef from PharmaSwiss
13 February 2013
SOBI gains EMA approval for change of Kineret producer; Novartis drops NIC002 project
23 January 2013
FDA approves SOBI's Kineret for the treatment of NOMID
8 January 2013
Biogen Idec files for US approval of hemophilia B treatment
7 January 2013
News briefs from Sanofi, Biogen/SOBI and Novartis
1 November 2012
Positive Ph III results for Biogen Idec and SOBI's hemophilia B agent
27 September 2012
Sobi and Biogen Idec flesh out details of hemophilia programs
6 February 2012
Sobi buys rights to novel neonatology treatment
16 January 2012
Pharming extends Ruconest deal with SOBI
16 August 2011
Symphogen raises 100 million euros in private equity round; regains rights to Sym110 from SOBI
10 January 2011
CEO leaves as Swedish Orphan Biovitrum moves into new phase
29 November 2010
US FDA and EMEA accepts AstraZeneca’s filing for vandetanib; SOBI gains orphan status for hemophilia A therapy in EU
23 September 2010
Pharming plans to file Rhucin BLA with US FDA by end 2010
31 August 2010
Biogen Idec and Swedish Orphan Biovitrum advance long-lasting hemophilia A therapy into registrational trial
12 July 2010
Showing 1-18 of 18 articles
- 1
- Elan makes "transformational" acquisitions and a divestment
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- SciClone gains China rights to Zensun's Neucardin
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
